Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: Results from the british isles lupus assessment group biologics register
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: Results from the british isles lupus assessment group biologics register
Objectives. To describe the baseline characteristics of SLE patients requiring biologic therapy in the UK and to explore short term efficacy and infection rates associated with rituximab (RTX) use. Methods. Patients commencing biologic therapy for refractory SLE and who consented to join BILAG-BR were analysed. Baseline characteristics, disease activity (BILAG 2004/SLEDAI-2K) and rates of infection over follow-up were analysed. Response was defined as loss of all A and B BILAG scores to41 B score with no new A/B scores in other organ systems at 6 months. Results. Two hundred and seventy SLE patients commenced biologic therapy from September 2010 to September 2015, most commonly RTX (n = 261). Two hundred and fifty (93%) patients were taking glucocorticoids at baseline at a median [interquartile range (IQR)] oral dose of 10mg (5-20 mg) daily. Response rates at 6 months were available for 68% of patients. The median (IQR) BILAG score was 15 (10-23) at baseline and 3 (2-12) at 6 months (P<0.0001). The median (IQR) SLEDAI-2K reduced from 8 (5-12) to 4 (0-7) (P<0.001). Response was achieved in 49% of patients. There was also a reduction in glucocorticoid use to a median (IQR) dose of 7.5mg (5-12 mg) at 6 months (P< 0.001). Serious infections occurred in 26 (10%) patients, being more frequent in the first 3 months post-RTX therapy. A higher proportion of early infections were non-respiratory (odds ratio = 1.98, 95% CI: 0.99, 3.9; P = 0.049). Conclusion. RTX is safe and is associated with improvement in disease activity in refractory SLE patients with concomitant reductions in glucocorticoid use. Early vigilance for infection post-infusion is important to further improve treatment risks and benefits.
Biologic therapy, Register, Rituximab, Systemic lupus erythematosus
470-479
McCarthy, Eoghan M.
9d9cb4aa-4a6e-4457-b8a6-d1ab4b9fa2ca
Sutton, Emily
d791b607-aa06-4c7a-b4d6-63034435fa1e
Nesbit, Stephanie
3fe42958-c7aa-485b-93b7-703e7b568210
White, James
97bdeed4-d6e2-4045-9eee-9a3d0697b9a4
Parker, Ben
c7d7df8e-7bea-4c4f-bd79-330108d15d59
Jayne, David
ac68590a-ccc5-4b29-972a-39d502f4a5a1
Griffiths, Bridget
832d47b3-c3f7-4aef-b44c-0c3ea14c12e6
Isenberg, WDavid A.
36106e15-ca18-4e96-a4a3-69a0eebe77f1
Rahman, Anisur
cb88abd6-00b3-44da-87bf-a7772844dc86
Gordon, Caroline
26c12bd7-98a2-4614-827d-6016b6480e89
D'Cruz, David P.
cc7a3c8b-8f8b-4051-8192-fc3636586a1b
Rhodes, Benjamin
ea4f6943-b2a7-4948-9dd2-c131bf3968a8
Lanyon, Peter
4d313d4e-2f09-4e39-a857-3ef82fce27d0
Vital, Edward M.
aca2f46f-a608-4132-adf3-e7afd16b3c17
Yee, Chee Seng
4bf73452-56d6-4e7e-b4a0-108df6e439a2
Edwards, Christopher J.
dcb27fec-75ea-4575-a844-3588bcf14106
Teh, Lee Suan
c6c19ae8-bbc3-445b-85f4-d2e89cf85430
Akil, Mohammed
701701a9-098d-48bc-9f2a-be6aa178c7a4
McHugh, Neil J.
adf2a50a-14ac-40f6-a60a-26e22ac65fda
Zoma, Asad
d18bce88-e6f4-442f-b94a-eae507aa9fea
Bruce, Ian N.
1375900a-3ac1-4235-a573-abfd8c21c37d
Gordon, Patrick
94179f70-cef2-41ec-9909-be63ced92fc7
Young-Min, Steven
81505ac0-9f46-490d-a9e0-2203bfecbde3
Stevens, Robert
77d9804f-1a7d-4047-ac2c-af30a53e7361
Prabu, Athiveer
79983aac-d0e5-435d-b047-f1601c3468f5
Batley, Mike
b195658e-b3c0-4643-85d2-dcb57e8f0f71
Gendi, Nagui
459488ff-6e04-449a-9c1f-64462dc75271
Dasgupta, Bhaskar
ed3e1cf7-24a7-438b-9b47-d2503e8c541a
Khamashta, Munther
30a044e5-cc8f-4cae-a198-0b2c7154717a
Hewins, Peter
268f1bc3-d55c-43d7-b938-7c57b04ee24f
Stratton, Richard J.
a3244701-31cb-4aec-b035-27cf06d60283
Chan, Antoni
e5a2c95c-d466-420b-aedf-014f1d078e5d
De Lord, Denise
a50915d0-96dc-43e7-9324-3a79a878abeb
King, Jon
7696a94c-00cd-4238-beaa-0ee810ae8d19
Dubey, Shirish
d0f1611a-8bb8-4ed8-9d6a-67ffafa1e268
O'Riordan, Edmond
47ce0e4b-8acb-42fa-92bd-6a689edf97cb
Shaffu, Shireen
8b4c60ec-74c0-4637-9c58-804e5f1db33e
Laversuch, Cathy
f885c19f-ba92-4c0c-93ce-f531cea8c54d
Sheeran, Thomas P.
7366b4e0-5f2f-4d01-aced-f54e2b75d570
Vermaak, Erin
dfcc977b-a543-4139-98bb-8993c737aac2
Erb, Nicola
de5eda4d-242f-4046-b442-cd308977a75c
Pyne, Debasish
48212c2e-3457-4878-91ea-2e8e2005f4c1
Jeffrey, Rachel
4b30a863-b05e-4f76-bccf-fff5f7b90bca
Youssef, Hazem
a1419786-f521-4e5f-a80d-fb0153bfcd6e
Al-Allaf, Wahab
9c06f75c-1764-44c6-b387-7bb1b8b23e63
Regan, Marian
6ecc4901-1780-4788-a4b2-50cba003d675
Kaul, Arvind
85de6897-cfc3-43f8-b831-596137bd68d3
On behalf of the British Isles Lupus Assessment Group Biologics Register
1 March 2018
McCarthy, Eoghan M.
9d9cb4aa-4a6e-4457-b8a6-d1ab4b9fa2ca
Sutton, Emily
d791b607-aa06-4c7a-b4d6-63034435fa1e
Nesbit, Stephanie
3fe42958-c7aa-485b-93b7-703e7b568210
White, James
97bdeed4-d6e2-4045-9eee-9a3d0697b9a4
Parker, Ben
c7d7df8e-7bea-4c4f-bd79-330108d15d59
Jayne, David
ac68590a-ccc5-4b29-972a-39d502f4a5a1
Griffiths, Bridget
832d47b3-c3f7-4aef-b44c-0c3ea14c12e6
Isenberg, WDavid A.
36106e15-ca18-4e96-a4a3-69a0eebe77f1
Rahman, Anisur
cb88abd6-00b3-44da-87bf-a7772844dc86
Gordon, Caroline
26c12bd7-98a2-4614-827d-6016b6480e89
D'Cruz, David P.
cc7a3c8b-8f8b-4051-8192-fc3636586a1b
Rhodes, Benjamin
ea4f6943-b2a7-4948-9dd2-c131bf3968a8
Lanyon, Peter
4d313d4e-2f09-4e39-a857-3ef82fce27d0
Vital, Edward M.
aca2f46f-a608-4132-adf3-e7afd16b3c17
Yee, Chee Seng
4bf73452-56d6-4e7e-b4a0-108df6e439a2
Edwards, Christopher J.
dcb27fec-75ea-4575-a844-3588bcf14106
Teh, Lee Suan
c6c19ae8-bbc3-445b-85f4-d2e89cf85430
Akil, Mohammed
701701a9-098d-48bc-9f2a-be6aa178c7a4
McHugh, Neil J.
adf2a50a-14ac-40f6-a60a-26e22ac65fda
Zoma, Asad
d18bce88-e6f4-442f-b94a-eae507aa9fea
Bruce, Ian N.
1375900a-3ac1-4235-a573-abfd8c21c37d
Gordon, Patrick
94179f70-cef2-41ec-9909-be63ced92fc7
Young-Min, Steven
81505ac0-9f46-490d-a9e0-2203bfecbde3
Stevens, Robert
77d9804f-1a7d-4047-ac2c-af30a53e7361
Prabu, Athiveer
79983aac-d0e5-435d-b047-f1601c3468f5
Batley, Mike
b195658e-b3c0-4643-85d2-dcb57e8f0f71
Gendi, Nagui
459488ff-6e04-449a-9c1f-64462dc75271
Dasgupta, Bhaskar
ed3e1cf7-24a7-438b-9b47-d2503e8c541a
Khamashta, Munther
30a044e5-cc8f-4cae-a198-0b2c7154717a
Hewins, Peter
268f1bc3-d55c-43d7-b938-7c57b04ee24f
Stratton, Richard J.
a3244701-31cb-4aec-b035-27cf06d60283
Chan, Antoni
e5a2c95c-d466-420b-aedf-014f1d078e5d
De Lord, Denise
a50915d0-96dc-43e7-9324-3a79a878abeb
King, Jon
7696a94c-00cd-4238-beaa-0ee810ae8d19
Dubey, Shirish
d0f1611a-8bb8-4ed8-9d6a-67ffafa1e268
O'Riordan, Edmond
47ce0e4b-8acb-42fa-92bd-6a689edf97cb
Shaffu, Shireen
8b4c60ec-74c0-4637-9c58-804e5f1db33e
Laversuch, Cathy
f885c19f-ba92-4c0c-93ce-f531cea8c54d
Sheeran, Thomas P.
7366b4e0-5f2f-4d01-aced-f54e2b75d570
Vermaak, Erin
dfcc977b-a543-4139-98bb-8993c737aac2
Erb, Nicola
de5eda4d-242f-4046-b442-cd308977a75c
Pyne, Debasish
48212c2e-3457-4878-91ea-2e8e2005f4c1
Jeffrey, Rachel
4b30a863-b05e-4f76-bccf-fff5f7b90bca
Youssef, Hazem
a1419786-f521-4e5f-a80d-fb0153bfcd6e
Al-Allaf, Wahab
9c06f75c-1764-44c6-b387-7bb1b8b23e63
Regan, Marian
6ecc4901-1780-4788-a4b2-50cba003d675
Kaul, Arvind
85de6897-cfc3-43f8-b831-596137bd68d3